Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Pfizer (NY:PFE)

25.38 +0.06 (+0.24%)
Official Closing Price Updated: 5:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
The Best Dividend Stocks I'd Buy Right Now
Via The Motley Fool
2 Stocks to Buy With Less Than $50
Via The Motley Fool
Topics Intellectual Property
Trump's 'Big, Beautiful Bill' Hands $5 Billion Win To Big Pharma: Report
Trump's $3.3 trillion domestic agenda bill, passed by the House on Thursday, includes a significant victory for pharmaceutical companies . 
Via Benzinga
Topics Government
Prediction: 3 Magnificent Stocks That'll Be Worth More Than Palantir by 2028
The parabolic ascent of artificial intelligence (AI) superstar Palantir Technologies may be short-lived. 
Via The Motley Fool
Topics Artificial Intelligence
3 Safe-and-Steady Stocks on Our Watchlist
By avoiding big swings, low-volatility stocks let investors focus on long-term fundamentals. These stocks may not be up 100% in a single year, but they offer a measured approach to building wealth over... 
Via StockStory
Explore the S&P500 index on Thursday and find out which stocks are the most active in today's session.
Let's have a look at what is happening on the US markets on Thursday. Below you can find the most active S&P500 stocks in today's session. 
Via Chartmill
RFK Jr. Influence Evident As Vaccine Chief Overrules Scientists, Limits COVID-19 Vaccine Approval
FDA vaccine head Vinay Prasad restricted Moderna and Novavax COVID vaccines to high-risk groups, overriding staff advice amid concerns about rare side effects. 
Via Benzinga
Recent Report Shows That Sen. Ron L Wyden Sold Up to $15K Worth of Pfizer Stock
Via Benzinga
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
Is Pfizer Stock a Yield Trap?
Via The Motley Fool
Topics Intellectual Property
3 Ultra-High-Yield Dividend Stocks -- Sporting an Average Yield of 9% -- Which Make for No-Brainer Buys in July
Three supercharged dividend stocks have the necessary catalysts to make their patient shareholders notably richer. 
Via The Motley Fool
Topics Bonds Economy
CDC Greenlights Vaccines From Pfizer, Moderna, GSK Amid Shakeup Of Advisory Panel
The agency expanded its RSV and meningococcal vaccine guidance to cover younger age groups and new formulations. 
Via Stocktwits
Topics Government
Huge Unusual Volume In Pfizer Put Options Signals Investors Bullish Outlook
Large unusual trading volume in Pfizer, Inc. put options that expire 30 days from now signals investors' bullish outlook on PFE stock. 
Via Talk Markets
Lawmakers Investigate Whether Pfizer Delayed COVID-19 Vaccine Results For Political Reasons
Via Benzinga
2 of Wall Street’s Favorite Stocks to Research Further and 1 to Question
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,... 
Via StockStory
Curious about the most active S&P500 stocks in today's session?
Let's have a look at what is happening on the US markets on Tuesday. Below you can find the most active S&P500 stocks in today's session. 
Via Chartmill
Dynamic Global Events Presents: The 6th Clinical Trial Agreements Summit
Via Investor Brand Network
Topics Intellectual Property
Ex-Pfizer Exec Pulled Into House Probe Over Alleged COVID Vaccine Delay Through 2020 Election
The committee cited remarks allegedly made by Philip Dormitzer at GSK, claiming that Pfizer’s top R&D leaders delayed clinical trial progress to avoid releasing results before the 2020 election. 
Via Stocktwits
Topics Government Law Enforcement
Can Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment?
The company announced a new drug that uses the same mechanism as Eli Lilly's retatrutide. 
Via Investor's Business Daily
3 No-Brainer Stocks to Buy for Under $100 Right Now
Via The Motley Fool
Topics Intellectual Property
CDC Vaccine Panel Overhauled by RFK Jr. Votes To Drop Mercury Preservative, Critics Sound Alarm
The panel also voted to recommend Merck’s RSV antibody drug Enflonsia for newborns whose mothers didn’t receive prenatal protection. 
Via Stocktwits
Pfizer Seeks Label Expansion For Hemophilia Drug After Promising Data
Pfizer's Hympavzi showed superior bleed control in hemophilia A and B patients with inhibitors, reducing bleeding rates and showing good tolerability. 
Via Benzinga
Tesla Senior Executive And Elon Musk Confidant Omead Afshar Leaves EV Giant Amid Dropping Sales, Days After Robotaxi Launch: Report
Afshar was promoted last year to oversee sales and manufacturing operations in North America and Europe. He previously worked in the office of the CEO. 
Via Stocktwits
Topics Artificial Intelligence
Pfizer’s Hemophilia Drug Meets Goals In Late-Stage Trial In Patients With Certain Antibodies
During the study, 48 people living with hemophilia were treated with Hympavzi and observed to have a 93% reduction in annualized bleeding rate in 12 months. 
Via Stocktwits
Topics Death
Pfizer Announces Positive Topline Phase 3 Results for HYMPAVZI™ in Hemophilia A or B with Inhibitors
From Pfizer Inc.
Via Business Wire
RFK Jr. Overhauls CDC Vaccine Panel, Sparking Expert Backlash, Boycott From Top Medical Group
Health Secretary Robert F. Kennedy Jr.'s newly reconstituted vaccine advisory panel is facing criticism from medical experts. 
Via Benzinga
Moderna, Pfizer, Novavax Draw Bearish Buzz Ahead Of CDC Panel With Vaccine Skeptics
RFK Jr.'s newly appointed CDC panel, half of whom oppose vaccines, prepares to review key data on COVID, RSV, and flu shots. 
Via Stocktwits
Pfizer Declares Third-Quarter 2025 Dividend
From Pfizer Inc.
Via Business Wire
Pfizer Invites Public to View and Listen to Webcast of August 5 Conference Call with Analysts
From Pfizer Inc.
Via Business Wire
3 Reasons PFE is Risky and 1 Stock to Buy Instead
Over the past six months, Pfizer’s shares (currently trading at $24.29) have posted a disappointing 8.5% loss while the S&P 500 was flat. This may have investors wondering how to approach the... 
Via StockStory
Topics Stocks
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.